Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 32

1.

Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Altaweel MM, Daniel E, Martin DF, Mittra RA, Grunwald JE, Lai MM, Melamud A, Morse LS, Huang J, Ferris FL 3rd, Fine SL, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group; Comparison of Age-related Macular Degeneration Treatments Trials CATT Research Group.

Ophthalmology. 2015 Feb;122(2):391-398.e5. doi: 10.1016/j.ophtha.2014.08.020. Epub 2014 Oct 11.

PMID:
25307130
2.

Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study.

Awh CC, Hawken S, Zanke BW.

Ophthalmology. 2015 Jan;122(1):162-9. doi: 10.1016/j.ophtha.2014.07.049. Epub 2014 Sep 4.

PMID:
25200399
3.

Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema.

Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group.

Ophthalmology. 2014 Oct;121(10):1904-14. doi: 10.1016/j.ophtha.2014.04.024. Epub 2014 Jun 4.

4.

Comparison of optical coherence tomography assessments in the comparison of age-related macular degeneration treatments trials.

Folgar FA, Jaffe GJ, Ying GS, Maguire MG, Toth CA; Comparison of Age-Related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2014 Oct;121(10):1956-65. doi: 10.1016/j.ophtha.2014.04.020. Epub 2014 May 15.

PMID:
24835760
5.

Author reply: To PMID 23972322.

Awh CC, Lane AM, Hawken S, Zanke B, Kim IK.

Ophthalmology. 2014 Aug;121(8):e39. doi: 10.1016/j.ophtha.2014.02.029. Epub 2014 May 2. No abstract available.

PMID:
24793507
6.

Sporadic visual acuity loss in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT).

Kim BJ, Ying GS, Huang J, Levy NE, Maguire MG; CATT Research Group.

Am J Ophthalmol. 2014 Jul;158(1):128-135.e10. doi: 10.1016/j.ajo.2014.04.004. Epub 2014 Apr 13.

PMID:
24727261
7.

VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Maguire MG, Martin DF; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT) Research Group.

JAMA Ophthalmol. 2014 May;132(5):521-7.

8.

CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration.

Awh CC, Lane AM, Hawken S, Zanke B, Kim IK.

Ophthalmology. 2013 Nov;120(11):2317-23. doi: 10.1016/j.ophtha.2013.07.039. Epub 2013 Aug 21.

PMID:
23972322
9.

Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.

Jaffe GJ, Martin DF, Toth CA, Daniel E, Maguire MG, Ying GS, Grunwald JE, Huang J; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2013 Sep;120(9):1860-70. doi: 10.1016/j.ophtha.2013.01.073. Epub 2013 May 1.

10.

Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT).

Hagstrom SA, Ying GS, Pauer GJ, Sturgill-Short GM, Huang J, Callanan DG, Kim IK, Klein ML, Maguire MG, Martin DF; Comparison of AMD Treatments Trials Research Group.

Ophthalmology. 2013 Mar;120(3):593-9. doi: 10.1016/j.ophtha.2012.11.037. Epub 2013 Jan 18.

11.

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration.

Ying GS, Huang J, Maguire MG, Jaffe GJ, Grunwald JE, Toth C, Daniel E, Klein M, Pieramici D, Wells J, Martin DF; Comparison of Age-related Macular Degeneration Treatments Trials Research Group.

Ophthalmology. 2013 Jan;120(1):122-9. doi: 10.1016/j.ophtha.2012.07.042. Epub 2012 Oct 6.

12.

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd.

Ophthalmology. 2012 Jul;119(7):1388-98. doi: 10.1016/j.ophtha.2012.03.053. Epub 2012 May 1.

13.

HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration.

Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P, Tuomi L.

Ophthalmology. 2012 Jun;119(6):1175-83. doi: 10.1016/j.ophtha.2011.12.016. Epub 2012 Feb 4.

PMID:
22306121
14.

A 29/30-gauge dual-chandelier illumination system for panoramic viewing during microincision vitrectomy surgery.

Sakaguchi H, Oshima Y, Nishida K, Awh CC.

Retina. 2011 Jun;31(6):1231-3. doi: 10.1097/IAE.0b013e31822091ca. No abstract available.

PMID:
21836412
15.

Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG.

Ophthalmology. 2011 Oct;118(10):2041-9. doi: 10.1016/j.ophtha.2011.02.038. Epub 2011 Jun 29.

PMID:
21715011
16.

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ.

N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.

17.

Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%.

Heier JS, Awh CC, Busbee BG, Waterbury LD, Daniel P, Stoller GL, Cleary TS.

Retina. 2009 Oct;29(9):1310-3. doi: 10.1097/IAE.0b013e3181b094e6.

PMID:
19934822
18.

Prophylactic treatment of age-related macular degeneration report number 2: 810-nanometer laser to eyes with drusen: bilaterally eligible patients.

Friberg TR, Brennen PM, Freeman WR, Musch DC; PTAMD Study Group.

Ophthalmic Surg Lasers Imaging. 2009 Nov-Dec;40(6):530-8. doi: 10.3928/15428877-20091030-01.

PMID:
19928717
19.

A more convenient chandelier system utilizing a 29-gauge optical fiber housed within a retractable 27-gauge needle.

Oshima Y, Awh CC, Tano Y.

Retina. 2008 Nov-Dec;28(10):1559-60; author reply 1560. doi: 10.1097/IAE.0b013e318187f177. No abstract available.

PMID:
18784618
20.

Novel mercury vapor illuminator combined with a 27/29-gauge chandelier light fiber for vitreous surgery.

Oshima Y, Chow DR, Awh CC, Sakaguchi H, Tano Y.

Retina. 2008 Jan;28(1):171-3. doi: 10.1097/IAE.0b013e31814fb0d3. No abstract available.

PMID:
18185157
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk